EASL 2013: Daclatasvir + Asunaprevir + BMS-791352 Looks Promising as Interferon-free Combo
- Details
- Category: HCV Treatment
- Published on Wednesday, 01 May 2013 00:00
- Written by Liz Highleyman
An all-oral regimen containing 3 next-generation antivirals taken for either 12 or 24 weeks produced sustained virological response in more than 90% of previously untreated genotype 1 chronic hepatitis C patients in a Phase 2a study, according to a late-breaking poster presentation at the EASL International Liver Congress(EASL 2013) in Amsterdam.
EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
- Written by Keith Alcorn
Currently available triple therapies for hepatitis C using HCV protease inhibitors carry a high risk of serious side effects for patients in the most urgent need of treatment, and these individuals have only a moderate chance of being cured, according to findings from studies of telaprevir and boceprevir treatment in cirrhotic patients at liver centers in France and Austria reported last week at the 48th International Liver Congress in Amsterdam. In the Austrian study almost 1 in 10 cirrhotic patients were hospitalized with sepsis during triple therapy.
EASL 2013: Truvada Works Best for Immune-Tolerant Hepatitis B Patients -- But Do They Need Treatment?
- Details
- Category: HBV Treatment
- Published on Monday, 29 April 2013 00:00
- Written by Liz Highleyman
A combination of tenofovir and emtricitabine (the drugs in Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant disease, researchers reported at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. The benefits of treatment at this early stage, however, remain uncertain.
EASL 2013: Hep C Quad Regimens Quashed, but Some Components Go Forward
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
- Written by Liz Highleyman
A pair of 4-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a set of presentations last week at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. While this type of quad regimen has little if any future, some of the component drugs remain promising.
EASL 2013: Second-generation Protease Inhibitor Faldaprevir Cures up to 80% of Genotype 1 Hepatitis C
- Details
- Category: HCV Treatment
- Published on Monday, 29 April 2013 00:00
- Written by Keith Alcorn
A second-generation HCV protease inhibitor, faldaprevir (formerly BI 201335), cured up to 80% of previously untreated people with genotype 1 hepatitis C virus infection when combined with pegylated interferon and ribavirin, Peter Ferenci of the Medical University of Vienna reported on Saturday at the EASL International Liver Congress (EASL 2013) in Amsterdam. A response gap was observed, however, between HCV subtypes 1a and 1b.
More Articles...
- EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- Coverage of the 2013 EASL International Liver Congress
- EASL 2013: MK-5172 Boosts Interferon/Ribavirin Response Regardless of IL28B Status
- EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower
Web Design and Development by